A detailed history of Price T Rowe Associates Inc transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 37,213 shares of RCUS stock, worth $536,983. This represents 0.0% of its overall portfolio holdings.

Number of Shares
37,213
Previous 36,498 1.96%
Holding current value
$536,983
Previous $556,000 2.34%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$13.69 - $18.01 $9,788 - $12,877
715 Added 1.96%
37,213 $569,000
Q2 2024

Aug 14, 2024

BUY
$14.59 - $18.48 $25,299 - $32,044
1,734 Added 4.99%
36,498 $556,000
Q1 2024

May 15, 2024

BUY
$14.83 - $20.18 $28,265 - $38,463
1,906 Added 5.8%
34,764 $657,000
Q4 2023

Feb 14, 2024

BUY
$13.43 - $19.63 $22,092 - $32,291
1,645 Added 5.27%
32,858 $628,000
Q3 2023

Nov 14, 2023

SELL
$17.62 - $23.54 $4.41 Million - $5.89 Million
-250,407 Reduced 88.92%
31,213 $561,000
Q2 2023

Aug 14, 2023

BUY
$16.97 - $22.03 $35,467 - $46,042
2,090 Added 0.75%
281,620 $5.72 Million
Q1 2023

May 15, 2023

SELL
$15.96 - $23.15 $3.61 Million - $5.24 Million
-226,217 Reduced 44.73%
279,530 $5.1 Million
Q4 2022

Feb 14, 2023

BUY
$19.7 - $35.71 $9.49 Million - $17.2 Million
481,848 Added 2016.18%
505,747 $10.5 Million
Q3 2022

Nov 14, 2022

BUY
$23.23 - $30.07 $143,979 - $186,373
6,198 Added 35.01%
23,899 $626,000
Q2 2022

Aug 15, 2022

SELL
$17.23 - $37.73 $29,911 - $65,499
-1,736 Reduced 8.93%
17,701 $449,000
Q1 2022

May 16, 2022

BUY
$28.92 - $41.83 $46,908 - $67,848
1,622 Added 9.1%
19,437 $613,000
Q4 2021

Feb 14, 2022

SELL
$31.38 - $48.47 $24,131 - $37,273
-769 Reduced 4.14%
17,815 $721,000
Q3 2021

Nov 15, 2021

SELL
$26.93 - $37.68 $1,050 - $1,469
-39 Reduced 0.21%
18,584 $648,000
Q2 2021

Aug 16, 2021

SELL
$22.75 - $35.77 $59,423 - $93,431
-2,612 Reduced 12.3%
18,623 $511,000
Q1 2021

May 17, 2021

SELL
$26.16 - $41.39 $235 - $372
-9 Reduced 0.04%
21,235 $596,000
Q4 2020

Feb 16, 2021

BUY
$17.0 - $32.36 $361,148 - $687,455
21,244 New
21,244 $551,000

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.04B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.